Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 38 articles:
HTML format
Text format



Single Articles


    November 2018
  1. POLUSANI SR, Huang YW, Huang G, Chen CW, et al
    Adipokines Deregulate Cellular Communication via Epigenetic Repression of Gap Junction Loci in Obese Endometrial Cancer.
    Cancer Res. 2018 Nov 2. pii: 0008-5472.CAN-18-1615.
    PubMed     Text format     Abstract available


    October 2018

  2. Correction: RSF1 Is a Positive Regulator of NFkappaB-induced Gene Expression Required for Ovarian Cancer Chemoresistance.
    Cancer Res. 2018;78:6024.
    PubMed     Text format    


    September 2018
  3. LIU M, Thomas SL, DeWitt AK, Zhou W, et al
    Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells.
    Cancer Res. 2018 Sep 5. pii: 0008-5472.CAN-17-3953.
    PubMed     Text format     Abstract available


    August 2018
  4. BYEON Y, Lee JW, Choi WS, Won JE, et al
    CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
    Cancer Res. 2018 Aug 16. pii: 0008-5472.CAN-17-3871.
    PubMed     Text format     Abstract available



  5. Correction: Significance of MAD2 Expression to Mitotic Checkpoint Control in Ovarian Cancer Cells.
    Cancer Res. 2018;78:4800.
    PubMed     Text format    


  6. BELANGER F, Fortier E, Dube M, Lemay JF, et al
    Replication Protein A Availability During DNA Replication Stress Is a Major Determinant of Cisplatin Resistance in Ovarian Cancer Cells.
    Cancer Res. 2018 Aug 2. pii: 0008-5472.CAN-18-0618.
    PubMed     Text format     Abstract available


    July 2018
  7. LU Y, Beeghly-Fadiel A, Wu L, Guo X, et al
    A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.
    Cancer Res. 2018 Jul 27. pii: 0008-5472.CAN-18-0951.
    PubMed     Text format     Abstract available



  8. Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
    Cancer Res. 2018;78:4100.
    PubMed     Text format    



  9. Correction: Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer.
    Cancer Res. 2018;78:4099.
    PubMed     Text format    



  10. Correction: FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.
    Cancer Res. 2018;78:3742.
    PubMed     Text format    


    June 2018

  11. Correction: Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
    Cancer Res. 2018;78:3402.
    PubMed     Text format    


  12. HIRST J, Pathak HB, Hyter S, Pessetto ZY, et al
    Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties.
    Cancer Res. 2018 Jun 11. pii: 0008-5472.CAN-17-3993.
    PubMed     Text format     Abstract available


    May 2018
  13. HAUTANIEMI S, Kozlowska E, Farkkila A, Vallius T, et al
    Mathematical modeling predicts response to chemotherapy and drug combinations in ovarian cancer.
    Cancer Res. 2018 May 16. pii: 0008-5472.CAN-17-3746.
    PubMed     Text format     Abstract available


  14. SALEM M, O'Brien JA, Bernaudo S, Shawer H, et al
    miRNA-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway.
    Cancer Res. 2018 May 10. pii: 0008-5472.CAN-17-3014.
    PubMed     Text format     Abstract available


  15. CARROLL MJ, Fogg KC, Patel HA, Krause HB, et al
    Alternatively activated macrophages upregulate mesothelial expression of P-selectin to enhance adhesion of ovarian cancer cells.
    Cancer Res. 2018 May 8. pii: 0008-5472.CAN-17-3341.
    PubMed     Text format     Abstract available


  16. LUO XL, Deng C, Su XD, Wang F, et al
    Loss of MED12 induces tumor dormancy in human epithelial ovarian cancer via downregulation of EGFR.
    Cancer Res. 2018 May 7. pii: 0008-5472.CAN-18-0134.
    PubMed     Text format     Abstract available



  17. Correction: Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERalpha in Tamoxifen-Associated Endometrial Carcinomas.
    Cancer Res. 2018;78:2446.
    PubMed     Text format    


    March 2018
  18. CONDELLO S, Sima LE, Ivan C, Cardenas H, et al
    Tissue transglutaminase regulates interactions between ovarian cancer stem cells and the tumor niche.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-17-2319.
    PubMed     Text format     Abstract available


    January 2018
  19. HA JH, Radhakrishnan R, Jayaraman M, Yan M, et al
    Lysophosphatidic Acid Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
    Cancer Res. 2018 Jan 31. pii: 0008-5472.CAN-17-1624.
    PubMed     Text format     Abstract available


  20. ZHANG Y, Li L, Wang L, Li J, et al
    Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer.
    Cancer Res. 2018 Jan 26. pii: 0008-5472.CAN-17-2460.
    PubMed     Text format     Abstract available


  21. CURRY E, Zeller C, Masrour N, Patten D, et al
    Genes predisposed to DNA hypermethylation during acquired resistance to chemotherapy are identified in ovarian tumors by bivalent chromatin domains at initial diagnosis.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-1650.
    PubMed     Text format     Abstract available


  22. RASHMI R, Huang X, Floberg JM, Elhammali A, et al
    Radio-resistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism.
    Cancer Res. 2018 Jan 16. pii: 0008-5472.CAN-17-2367.
    PubMed     Text format     Abstract available


  23. LU Y, Hu Z, Mangala LS, Stine ZE, et al
    MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
    Cancer Res. 2018;78:64-74.
    PubMed     Text format     Abstract available


    December 2017
  24. KANG J, Shin SH, Yoon H, Huh J, et al
    FIH is an oxygen sensor in ovarian cancer for G9a/GLP-driven epigenetic regulation of metastasis-related genes.
    Cancer Res. 2017 Dec 19. pii: 0008-5472.CAN-17-2506.
    PubMed     Text format     Abstract available


  25. SHANG C, Wang W, Liao Y, Chen Y, et al
    LNMICC promotes nodal metastasis of cervical cancer by reprogramming fatty acid metabolism.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-2356.
    PubMed     Text format     Abstract available


  26. FANG F, Cardenas H, Huang H, Jiang G, et al
    Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Re-sensitization to Platinum Drugs.
    Cancer Res. 2017 Dec 11. pii: 0008-5472.CAN-17-1492.
    PubMed     Text format     Abstract available


    November 2017
  27. HIRAMATSU K, Serada S, Enomoto T, Takahashi Y, et al
    LSR antibody therapy inhibits ovarian epithelial tumor growth by inhibiting lipid uptake.
    Cancer Res. 2017 Nov 29. pii: 0008-5472.CAN-17-0910.
    PubMed     Text format     Abstract available


    October 2017
  28. HOUSE CD, Jordan E, Hernandez L, Ozaki M, et al
    NF-kB promotes ovarian tumorigenesis via classical pathways supporting proliferative cancer cells and alternative pathways supporting ALDH+ cancer stem-like cells.
    Cancer Res. 2017 Oct 26. pii: canres.0366.2017.
    PubMed     Text format     Abstract available


  29. WU X, Serna VA, Thomas J, Qiang W, et al
    Subtype-specific cancer-associated fibroblasts contribute to the pathogenesis of uterine leiomyoma.
    Cancer Res. 2017 Oct 20. pii: canres.1744.2017.
    PubMed     Text format     Abstract available


  30. PAYEN VL, Hsu MY, Radecke KS, Wyart E, et al
    Monocarboxylate Transporter MCT1 Promotes Tumor Metastasis Independently of Its Activity as a Lactate Transporter.
    Cancer Res. 2017;77:5591-5601.
    PubMed     Text format     Abstract available


  31. CICHOCKI F, Valamehr B, Bjordahl R, Zhang B, et al
    GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
    Cancer Res. 2017;77:5664-5675.
    PubMed     Text format     Abstract available


  32. LAMICHHANE P, Karyampudi L, Shreeder B, Krempski J, et al
    IL-10 release upon PD-1 blockade sustains immunosuppression in ovarian cancer.
    Cancer Res. 2017 Oct 9. pii: canres.0740.2017.
    PubMed     Text format     Abstract available


  33. GALL VA, Philips AV, Qiao N, Clise-Dwyer K, et al
    Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells.
    Cancer Res. 2017;77:5374-5383.
    PubMed     Text format     Abstract available


    September 2017
  34. YIN X, Jing Y, Cai MC, Ma P, et al
    Clonality, heterogeneity and evolution of synchronous bilateral ovarian cancer.
    Cancer Res. 2017 Sep 28. pii: canres.1461.2017.
    PubMed     Text format     Abstract available


  35. FALCETTA F, Bizzaro F, D'Agostini E, Bani MR, et al
    Modeling cytostatic and cytotoxic responses to new treatment regimens for ovarian cancer.
    Cancer Res. 2017 Sep 26. pii: canres.1099.2017.
    PubMed     Text format     Abstract available



  36. Retraction: CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor alpha and Estrogen Receptor beta Expressions.
    Cancer Res. 2017;77:5211.
    PubMed     Text format    


  37. SONG KH, Choi CH, Lee HJ, Oh SJ, et al
    HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.
    Cancer Res. 2017;77:5039-5053.
    PubMed     Text format     Abstract available


    July 2017
  38. PIACENTE F, Caffa I, Ravera S, Sociali G, et al
    Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Cancer Res. 2017;77:3857-3869.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: